GI ASCO 2023 Highlights with Dr. Mark Lewis

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

Discussing GI ASCO 2023 Highlights – practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.

  • SPOTLIGHT – Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
  • NAPOLI3 – Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
  • Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
  • MOUNTAINEER – FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
  • SUNLIGHT – Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology